Product Code: GMDHC07966CDB
Summary
Global Markets Direct's, 'Biogen, Inc. - Product Pipeline Review - 2016', provides an overview of the Biogen, Inc.'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Biogen, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Biogen, Inc.
- The report provides overview of Biogen, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Biogen, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Biogen, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Biogen, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Biogen, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biogen, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Biogen, Inc. Snapshot
- Biogen, Inc. Overview
- Key Information
- Key Facts
- Biogen, Inc. - Research and Development Overview
- Biogen, Inc. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Partnered Products
- Partnered Products/Combination Treatment Modalities
- Pipeline Products - Out-Licensed Products
- Out-Licensed Products/Combination Treatment Modalities
- Biogen, Inc. - Pipeline Products Glance
- Biogen, Inc. - Late Stage Pipeline Products
- Pre-Registration Products/Combination Treatment Modalities
- Phase III Products/Combination Treatment Modalities
- Biogen, Inc. - Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- Biogen, Inc. - Early Stage Pipeline Products
- Preclinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Biogen, Inc. - Drug Profiles
- coagulation factor IX (recombinant), Fc fusion protein
- Product Description
- Mechanism of Action
- R&D Progress
- rituximab
- Product Description
- Mechanism of Action
- R&D Progress
- aducanumab
- Product Description
- Mechanism of Action
- R&D Progress
- amiselimod hydrochloride
- Product Description
- Mechanism of Action
- R&D Progress
- BG-00011
- Product Description
- Mechanism of Action
- R&D Progress
- natalizumab
- Product Description
- Mechanism of Action
- R&D Progress
- opicinumab
- Product Description
- Mechanism of Action
- R&D Progress
- raxatrigine hydrochloride
- Product Description
- Mechanism of Action
- R&D Progress
- BG-00001
- Product Description
- Mechanism of Action
- R&D Progress
- BIIB-054
- Product Description
- Mechanism of Action
- R&D Progress
- BIIB-059
- Product Description
- Mechanism of Action
- R&D Progress
- BIIB-061
- Product Description
- Mechanism of Action
- R&D Progress
- BIIB-063
- Product Description
- Mechanism of Action
- R&D Progress
- dapirolizumab pegol
- Product Description
- Mechanism of Action
- R&D Progress
- 5-D10
- Product Description
- Mechanism of Action
- R&D Progress
- CNV-1061436
- Product Description
- Mechanism of Action
- R&D Progress
- CNV-3000164
- Product Description
- Mechanism of Action
- R&D Progress
- CNV-3000223
- Product Description
- Mechanism of Action
- R&D Progress
- Gene Therapy for Hemophilia B
- Product Description
- Mechanism of Action
- R&D Progress
- NI-105
- Product Description
- Mechanism of Action
- R&D Progress
- NI-205
- Product Description
- Mechanism of Action
- R&D Progress
- PRT-2761
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Protein to Replace Factor VIII for Hemophilia A
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Antagonize GPR-84 for Chronic Pain
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Inhibit mPGES-1 for Chronic Pain
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Agonize ROR-Gamma for Autoimmune Disease
- Product Description
- Mechanism of Action
- R&D Progress
- Biogen, Inc. - Pipeline Analysis
- Biogen, Inc. - Pipeline Products by Target
- Biogen, Inc. - Pipeline Products by Route of Administration
- Biogen, Inc. - Pipeline Products by Molecule Type
- Biogen, Inc. - Pipeline Products by Mechanism of Action
- Biogen, Inc. - Recent Pipeline Updates
- Biogen, Inc. - Dormant Projects
- Biogen, Inc. - Discontinued Pipeline Products
- Discontinued Pipeline Product Profiles
- baminercept alfa
- BG-00010
- BIIB-023
- clenoliximab
- CNF-1010
- dexpramipexole dihydrochloride
- naxifylline
- Biogen, Inc. - Company Statement
- Biogen, Inc. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Biogen, Inc. - Key Manufacturing Facilities
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Biogen, Inc., Key Information
- Biogen, Inc., Key Facts
- Biogen, Inc. - Pipeline by Indication, 2016
- Biogen, Inc. - Pipeline by Stage of Development, 2016
- Biogen, Inc. - Monotherapy Products in Pipeline, 2016
- Biogen, Inc. - Partnered Products in Pipeline, 2016
- Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
- Biogen, Inc. - Out-Licensed Products in Pipeline, 2016
- Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
- Biogen, Inc. - Pre-Registration, 2016
- Biogen, Inc. - Phase III, 2016
- Biogen, Inc. - Phase II, 2016
- Biogen, Inc. - Phase I, 2016
- Biogen, Inc. - Preclinical, 2016
- Biogen, Inc. - Discovery, 2016
- Biogen, Inc. - Pipeline by Target, 2016
- Biogen, Inc. - Pipeline by Route of Administration, 2016
- Biogen, Inc. - Pipeline by Molecule Type, 2016
- Biogen, Inc. - Pipeline Products by Mechanism of Action, 2016
- Biogen, Inc. - Recent Pipeline Updates, 2016
- Biogen, Inc. - Dormant Developmental Projects,2016
- Biogen, Inc. - Discontinued Pipeline Products, 2016
- Biogen, Inc., Other Locations
- Biogen, Inc., Subsidiaries
- Biogen, Inc., Key Manufacturing Facilities
List of Figures
- Biogen, Inc. - Pipeline by Top 10 Indication, 2016
- Biogen, Inc. - Pipeline by Stage of Development, 2016
- Biogen, Inc. - Monotherapy Products in Pipeline, 2016
- Biogen, Inc. - Partnered Products in Pipeline, 2016
- Biogen, Inc. - Out-Licensed Products in Pipeline, 2016
- Biogen, Inc. - Pipeline by Top 10 Target, 2016
- Biogen, Inc. - Pipeline by Route of Administration, 2016
- Biogen, Inc. - Pipeline by Molecule Type, 2016
- Biogen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
